At the end of the Teva conference call, in response to a queation from Corey Davis, Teva stated that the UNIT growth for Copaxone in the US was 10-11%. During that same period, Tysabri's UNIT growth was 24-25%. So in the face of strong head winds from PML, Tysabri's UNIT growth in the US more than doubled that of Copaxone (on a percentage basis) over the EXACT same period of time.
Market Data 
Markets 
AI
